148 related articles for article (PubMed ID: 16552629)
1. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
Solomayer EF; Becker S; Pergola-Becker G; Bachmann R; Krämer B; Vogel U; Neubauer H; Wallwiener D; Huober J; Fehm TN
Breast Cancer Res Treat; 2006 Jul; 98(2):179-84. PubMed ID: 16552629
[TBL] [Abstract][Full Text] [Related]
2. The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD; Banys M; Meier-Stiegen F; Hahn M; Röhm C; Hoffmann J; Helms G; Taran FA; Wallwiener M; Walter C; Neubauer H; Wallwiener D; Fehm T
Breast Cancer Res Treat; 2013 Apr; 138(2):509-17. PubMed ID: 23494674
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
Schindlbeck C; Kampik T; Janni W; Rack B; Jeschke U; Krajewski S; Sommer H; Friese K
Breast Cancer Res; 2005; 7(6):R1174-85. PubMed ID: 16457698
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
[TBL] [Abstract][Full Text] [Related]
5. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
6. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
[TBL] [Abstract][Full Text] [Related]
7. Detection of disseminated tumor cells in patients with gynecological cancers.
Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
[TBL] [Abstract][Full Text] [Related]
8. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
9. Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
Becker S; Becker-Pergola G; Fehm T; Wallwiener D; Solomayer EF
Anticancer Res; 2005; 25(3B):2171-5. PubMed ID: 16158960
[TBL] [Abstract][Full Text] [Related]
10. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Balic M; Lin H; Young L; Hawes D; Giuliano A; McNamara G; Datar RH; Cote RJ
Clin Cancer Res; 2006 Oct; 12(19):5615-21. PubMed ID: 17020963
[TBL] [Abstract][Full Text] [Related]
11. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.
Fehm T; Becker S; Pergola-Becker G; Krämer B; Gruber I; Sotlar K; Kurek R; Wallwiener D; Solomayer E
Anticancer Res; 2004; 24(6):4211-6. PubMed ID: 15736474
[TBL] [Abstract][Full Text] [Related]
12. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
[TBL] [Abstract][Full Text] [Related]
13. Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases.
Kasimir-Bauer S; Otterbach F; Oberhoff C; Schmid KW; Kimmig R; Seeber S
Int J Mol Med; 2003 Dec; 12(6):969-75. PubMed ID: 14612976
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
15. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor.
Krawczyk N; Banys M; Neubauer H; Solomayer EF; Gall C; Hahn M; Becker S; Bachmann R; Wallwiener D; Fehm T
Anticancer Res; 2009 Oct; 29(10):4019-24. PubMed ID: 19846945
[TBL] [Abstract][Full Text] [Related]
16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
17. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern.
Effenberger KE; Borgen E; Eulenburg CZ; Bartkowiak K; Grosser A; Synnestvedt M; Kaaresen R; Brandt B; Nesland JM; Pantel K; Naume B
Breast Cancer Res Treat; 2011 Feb; 125(3):729-38. PubMed ID: 20449649
[TBL] [Abstract][Full Text] [Related]
18. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Ignatiadis M; Kallergi G; Ntoulia M; Perraki M; Apostolaki S; Kafousi M; Chlouverakis G; Stathopoulos E; Lianidou E; Georgoulias V; Mavroudis D
Clin Cancer Res; 2008 May; 14(9):2593-600. PubMed ID: 18451221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
